Asensus Surgical (NYSEAMERICAN:ASXC - Get Free Report) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a report released on Thursday, Marketbeat Ratings reports. They presently have a $0.35 price objective on the stock, down from their prior price objective of $2.00. HC Wainwright's price objective suggests a potential upside of 29.63% from the stock's current price.
Asensus Surgical Stock Performance
ASXC opened at $0.27 on Thursday. Asensus Surgical has a 52 week low of $0.20 and a 52 week high of $0.86.
Asensus Surgical (NYSEAMERICAN:ASXC - Get Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). Asensus Surgical had a negative net margin of 914.46% and a negative return on equity of 135.94%. The business had revenue of $5.43 million for the quarter. Sell-side analysts expect that Asensus Surgical will post -0.19 earnings per share for the current year.
Institutional Trading of Asensus Surgical
A number of large investors have recently made changes to their positions in the company. Masters Capital Management LLC raised its position in Asensus Surgical by 8.5% in the 2nd quarter. Masters Capital Management LLC now owns 2,000,000 shares of the company's stock valued at $1,010,000 after purchasing an additional 157,000 shares during the last quarter. Avantax Planning Partners Inc. raised its position in shares of Asensus Surgical by 773.0% in the third quarter. Avantax Planning Partners Inc. now owns 112,936 shares of the company's stock valued at $30,000 after buying an additional 100,000 shares during the last quarter. Mirador Capital Partners LP boosted its stake in Asensus Surgical by 83.2% in the 3rd quarter. Mirador Capital Partners LP now owns 110,000 shares of the company's stock worth $30,000 after buying an additional 49,961 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Asensus Surgical by 68.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 210,737 shares of the company's stock valued at $133,000 after purchasing an additional 85,487 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Asensus Surgical during the 2nd quarter worth approximately $106,000. 9.35% of the stock is currently owned by hedge funds and other institutional investors.
Asensus Surgical Company Profile
(
Get Free Report)
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
Recommended Stories
Before you consider Asensus Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Asensus Surgical wasn't on the list.
While Asensus Surgical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
